Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Bevacizumab is an anti-vascular endothelial growth factor monoclonal antibody that may prolong survival in ovarian and cervical cancer when given in combination with chemotherapy. It works by blocking the signalling pathways that are required for tumour angiogenesis, potentially limiting the cancer's ability to grow and spread. Hypertension is a known side effect of all angiogenesis inhibitors and could lead to interruption or premature discontinuation of effective anti-cancer treatment. Hypertension may also act as a barrier to the initiation of such treatment. In this review, we aim to present clear and practical recommendations on the management of blood pressure in ovarian and cervical cancer patients before, during and after bevacizumab treatment. This guidance covers considerations before initiating bevacizumab therapy and recommendations on the management of patients who develop hypertension, or who experience worsening of pre-existing hypertension, during bevacizumab treatment, and once the course of bevacizumab has been completed. These recommendations were developed collaboratively by a group of clinicians, comprising cardiologists, oncologists, a general practitioner and specialist oncology nurses, with expertise and practical experience in either oncology or hypertension. The aim of these recommendations is to support oncologists with hypertension assessment and management to facilitate starting or continuing bevacizumab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“No increase in blood pressure with aspirin”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [39]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“3/1 mm Hg increase with nonselective NSAIDs”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [39]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“No difference or an increase of up to 3/1 mm Hg with celecoxib”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [39]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“NSAIDs can antagonize the effects of RAAS-inhibitors and beta blockers”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [39]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“2/1 mm Hg increase with SNRI (selective norepinephrine and serotonin reuptake inhibitors)”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [39]
Experimental — accuracy not yet measured
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000065 · Cited by 7,391
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
Law, M. R., Morris, J. K., & Wald, N. J. (2009) · BMJ · doi:10.1136/bmj.b1665 · Cited by 2,775
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw211 · Cited by 2,544
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., Fowler, J., Greer, B. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104390 · Cited by 2,404 · cited 1×
“These trials demonstrated significant benefits in progression-free survival and overall survival in patients treated with bevacizumab compared with those not treated with bevacizumab.(33,36,38,39) Patients with hypertension were not excluded from these trials unless the condition was uncontrolled, despite antihyperten…”
BackgroundA Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,172
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.654 · Cited by 1,795
Rapsomaniki, E., Timmis, A., George, J., Pujades-Rodriguez, M., Shah, A. D., Denaxas, S., White, I. R., Caulfield, M. J., Deanfield, J. E., Smeeth, L., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60685-1 · Cited by 1,643
Cited by
2020 International Society of Hypertension Global Hypertension Practice Guidelines
Unger, T., Borghi, C., Charchar, F., Khan, N. A., Poulter, N. R., Prabhakaran, D., Ramirez, A., Schlaich, M., Stergiou, G. S., Tomaszewski, M., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15026 · Cited by 4,132
2020 International Society of Hypertension global hypertension practice guidelines
Unger, T., Borghi, C., Charchar, F., Khan, N. A., Poulter, N. R., Prabhakaran, D., Ramirez, A., Schlaich, M., Stergiou, G. S., Tomaszewski, M., et al. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002453 · Cited by 1,283
Herrmann, J., Lenihan, D., Armenian, S., Barac, A., Blaes, A., Cardinale, D., Carver, J., Dent, S., Ky, B., Lyon, A. R., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab674 · Cited by 645
Exploiting the folate receptor α in oncology
Scaranti, M., Cojocaru, E., Banerjee, S., & Banerji, U. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0339-5 · Cited by 593
Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy
Yetkin-Arik, B., Kastelein, A. W., Klaassen, I., Jansen, C. H. J. R., Latul, Y. P., Vittori, M., Bırı, A., Kahraman, K., Griffioen, A. W., Amant, F. C., et al. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188446 · Cited by 97
Metadata
- Authors
- Plummer, C., Michael, A., Shaikh, G., Stewart, M., Buckley, L., Miles, T., Ograbek, A., & McCormack, T.
- Affiliations
- Freeman Hospital (GB)
- Royal Surrey County Hospital (GB)
- James Cook University Hospital (GB)
- Hull University Teaching Hospitals NHS Trust (GB)
- Royal United Hospital Bath NHS Trust (GB)
- Roche (United Kingdom) (GB)
- Hull York Medical School (GB)
- Corresponding author
- Plummer, Chris
- Venue
- British Journal of Cancer
- Published
- 2019-06-11
- Volume
- 121
- Issue
- 2
- Pages
- 109-116
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC6738076
- OpenAlex
- W2951382000
- Cited by
- 52
- References
- 69
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 6 · 2023: 9 · 2022: 7 · 2021: 12 · 2020: 6 · 2019: 2
- FWCI
- 1.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- British Journal of Cancer (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
- Keywords
- hypertension, bevacizumab, ovarian cancer, cervical cancer, anti-angiogenic therapy, blood pressure control, treatment discontinuation, pre-existing hypertension
- MeSH terms
- Bevacizumab, Uterine Cervical Neoplasms, Clinical Trials as Topic, Female, Humans, Hypertension, Ovarian Neoplasms, Angiogenesis Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK. https://app.cochat.ai/papers/10.1038/s41416-019-0481-y
- The paper
- Plummer, C., Michael, A., Shaikh, G., Stewart, M., Buckley, L., Miles, T., Ograbek, A., & McCormack, T. (2019). Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK. British Journal of Cancer. https://doi.org/10.1038/s41416-019-0481-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.